Year |
Citation |
Score |
2016 |
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, et al. A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors. Cancer Discovery. PMID 27872130 DOI: 10.1158/2159-8290.Cd-16-0512 |
0.309 |
|
2016 |
Budha NR, Ji T, Musib L, Eppler S, Dresser M, Chen Y, Jin JY. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clinical Pharmacokinetics. PMID 27225997 DOI: 10.1007/S40262-016-0412-5 |
0.366 |
|
2016 |
Tolcher A, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Fairbrother WJ, Wong H, Budha N, Darbonne WC, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera CC, Infante JR. A PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF CUDC-427, A POTENT, ORAL, MONOVALENT IAP ANTAGONIST, IN PATIENTS WITH REFRACTORY SOLID TUMORS. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27076626 DOI: 10.1158/1078-0432.Ccr-16-0308 |
0.358 |
|
2016 |
Bonate PL, Ahamadi M, Budha N, de la Peña A, Earp JC, Hong Y, Karlsson MO, Ravva P, Ruiz-Garcia A, Struemper H, Wade JR. Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26837775 DOI: 10.1007/S10928-016-9464-2 |
0.353 |
|
2015 |
Chen Y, Ma F, Lu T, Budha N, Jin JY, Kenny JR, Wong H, Hop CE, Mao J. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Clinical Pharmacokinetics. PMID 26692192 DOI: 10.1007/S40262-015-0352-5 |
0.387 |
|
2015 |
Han K, Jin JY, Marchand M, Eppler S, Choong N, Hack SP, Tikoo N, Bruno R, Dresser M, Musib L, Budha NR. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. PMID 26365290 DOI: 10.1200/Jco.2015.33.15_Suppl.2573 |
0.327 |
|
2015 |
Budha NR, Leabman M, Jin JY, Wada DR, Baruch A, Peng K, Tingley WG, Davis JD. Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. The Aaps Journal. 17: 881-90. PMID 25823668 DOI: 10.1208/S12248-015-9750-8 |
0.369 |
|
2014 |
Peng K, Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha N, Leabman M, Song A, Kaur S, Fischer SK. Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study. Mabs. 6: 1500-8. PMID 25484037 DOI: 10.4161/Mabs.36208 |
0.332 |
|
2014 |
Yago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ding X, Dean B, Salphati L, Budha N, Jin JY, Dresser MJ, Ware JA. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. The Aaps Journal. 16: 1358-65. PMID 25274610 DOI: 10.1208/S12248-014-9673-9 |
0.381 |
|
2013 |
Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Molecular Pharmaceutics. 10: 4055-62. PMID 24044612 DOI: 10.1021/Mp400403S |
0.345 |
|
2013 |
Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 2104-13. PMID 24041744 DOI: 10.1124/Dmd.113.053926 |
0.397 |
|
2013 |
Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharmaceutics & Drug Disposition. 34: 141-54. PMID 23225350 DOI: 10.1002/Bdd.1830 |
0.306 |
|
2013 |
Tingley W, Luca D, Leabman M, Budha N, Kahn R, Baruch A, Cowan K, Davis JC. GW24-e2907 Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study Heart. 99: A153.2-A153. DOI: 10.1136/Heartjnl-2013-304613.423 |
0.352 |
|
2013 |
Tingley W, Luca D, Leabman M, Budha N, Kahn R, Baruch A, Cowan K, Davis JC. Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study European Heart Journal. 34: P4183-P4183. DOI: 10.1093/Eurheartj/Eht309.P4183 |
0.353 |
|
2012 |
Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, Darbonne WC, Gould SE, Steigerwalt R, Erickson R, Hop CE, LoRusso P, Eckhardt SG, Wagner A, Chan IT, et al. Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicological Sciences : An Official Journal of the Society of Toxicology. 130: 205-13. PMID 22843607 DOI: 10.1093/Toxsci/Kfs235 |
0.333 |
|
2012 |
Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the achilles heel of targeted therapy Clinical Pharmacology and Therapeutics. 92: 203-213. PMID 22739140 DOI: 10.1038/Clpt.2012.73 |
0.329 |
|
2012 |
Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). Journal of Medicinal Chemistry. 55: 4101-13. PMID 22413863 DOI: 10.1021/Jm300060K |
0.351 |
|
2011 |
Budha NR, Kovar A, Meibohm B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. The Aaps Journal. 13: 650-61. PMID 22005901 DOI: 10.1208/S12248-011-9302-9 |
0.525 |
|
2011 |
Yan Y, Wagle M, Punnoose E, Musib L, Budha N, Nannini M, Lin K, Liederer BM, Murli S, Ramakrishnan V, Patel P, Cervantes A, Tabernero J. Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B154 |
0.353 |
|
2009 |
Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinburgh, Scotland). 89: 378-85. PMID 19748318 DOI: 10.1016/J.Tube.2009.08.002 |
0.573 |
|
2008 |
Zhang Y, Mehrotra N, Budha NR, Christensen ML, Meibohm B. A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens. Clinica Chimica Acta; International Journal of Clinical Chemistry. 398: 105-12. PMID 18796299 DOI: 10.1016/J.Cca.2008.08.023 |
0.501 |
|
2008 |
Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, Scherman MS, Cho SH, McNeil MR, Lenaerts AJ, Franzblau SG, Meibohm B, Lee RE. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. The Journal of Antimicrobial Chemotherapy. 62: 1037-45. PMID 18693235 DOI: 10.1093/Jac/Dkn307 |
0.55 |
|
2008 |
Budha NR, Mehrotra N, Tangallapally R, Rakesh, Qi J, Daniels AJ, Lee RE, Meibohm B. Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. The Aaps Journal. 10: 157-65. PMID 18446516 DOI: 10.1208/S12248-008-9017-8 |
0.556 |
|
2008 |
Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs. Current Medicinal Chemistry. 15: 809-25. PMID 18393850 DOI: 10.2174/092986708783955509 |
0.573 |
|
2007 |
Tangallapally RP, Sun D, Rakesh, Budha N, Lee RE, Lenaerts AJ, Meibohm B, Lee RE. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorganic & Medicinal Chemistry Letters. 17: 6638-42. PMID 17937983 DOI: 10.1016/J.Bmcl.2007.09.048 |
0.561 |
|
Low-probability matches (unlikely to be authored by this person) |
2017 |
Baruch A, Luca D, Kahn RS, Cowan KJ, Leabman M, Budha NR, Chiu CP, Wu Y, Kirchhofer D, Peterson A, Davis JC, Tingley WG. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9. Clinical Cardiology. PMID 28326559 DOI: 10.1002/Clc.22687 |
0.298 |
|
2018 |
Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson N, Friberg L. A PKPD analysis of circulating biomarkers and their relationship to tumor response in atezolizumab-treated non-small cell lung cancer patients. Clinical Pharmacology and Therapeutics. PMID 30058723 DOI: 10.1002/Cpt.1198 |
0.294 |
|
2013 |
Budha NR, Benet LZ, Ware JA. Response to "drug interactions produced by proton pump inhibitors: Not simply a ph effect" Clinical Pharmacology and Therapeutics. 93: 151. PMID 23169432 DOI: 10.1038/Clpt.2012.206 |
0.291 |
|
2017 |
Baruch A, Mosesova S, Davis JD, Budha N, Vilimovskij A, Kahn R, Peng K, Cowan KJ, Harris LP, Gelzleichter T, Lehrer J, Davis JC, Tingley WG. Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). The American Journal of Cardiology. PMID 28343601 DOI: 10.1016/J.Amjcard.2017.02.020 |
0.288 |
|
2013 |
Yue Q, Mulder T, Rudewicz PJ, Solon E, Budha N, Ware JA, Lyssikatos J, Hop CE, Wong H, Khojasteh SC. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 508-17. PMID 23223496 DOI: 10.1124/Dmd.112.047019 |
0.287 |
|
2022 |
Budha N, Wu CY, Tang Z, Yu T, Liu L, Xu F, Gao Y, Li R, Zhang Q, Wan Y, Sahasranaman S. Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors. Cpt: Pharmacometrics & Systems Pharmacology. PMID 36330700 DOI: 10.1002/psp4.12880 |
0.28 |
|
2013 |
Tolcher AW, Papadopoulos KP, Patnaik A, Fairbrother WJ, Wong H, Budha NR, Darbonne WC, Peale FV, Mamounas MJ, Royer-Joo S, Yu R, Portera CC, Bendell JC, Burris HA, Infante JR. Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. Journal of Clinical Oncology. 31: 2503-2503. DOI: 10.1200/Jco.2013.31.15_Suppl.2503 |
0.28 |
|
2013 |
Shin YG, Jones SA, Murakami SC, Budha N, Ware J, Wong H, Buonarati MH, Dean B, Hop CE. Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0152 in human plasma using solid-phase extraction. Biomedical Chromatography : Bmc. 27: 102-10. PMID 22623056 DOI: 10.1002/Bmc.2754 |
0.272 |
|
2013 |
Yago MR, Frymoyer AR, Smelick GS, Frassetto LA, Budha NR, Dresser MJ, Ware JA, Benet LZ. Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. Molecular Pharmaceutics. 10: 4032-7. PMID 23980906 DOI: 10.1021/Mp4003738 |
0.259 |
|
2018 |
Baruch A, Mosesova S, Davis JD, Budha N, Vilimovskij A, Kahn R, Peng K, Cowan KJ, Harris LP, Gelzleichter T, Lehrer J, Davis JC, Tingley WG. Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583. The American Journal of Cardiology. PMID 29448977 DOI: 10.1016/J.Amjcard.2018.01.010 |
0.239 |
|
2018 |
McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, ... ... Budha N, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet. Oncology. PMID 29449192 DOI: 10.1016/S1470-2045(18)30078-0 |
0.221 |
|
2023 |
Frentzas S, Kao S, Gao R, Zheng H, Rizwan A, Budha N, de la Hoz Pedroza L, Tan W, Meniawy T. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. Journal For Immunotherapy of Cancer. 11. PMID 37857528 DOI: 10.1136/jitc-2022-005829 |
0.214 |
|
2024 |
Yu T, Liu X, Wu CY, Tang Z, Wang H, Schnell P, Wan Y, Wang K, Liu L, Gao Y, Sahasranaman S, Budha N. Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors. Clinical and Translational Science. 17: e13769. PMID 38515348 DOI: 10.1111/cts.13769 |
0.213 |
|
2021 |
Rotte A, Sahasranaman S, Budha N. Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. Biomedicines. 9. PMID 34572463 DOI: 10.3390/biomedicines9091277 |
0.213 |
|
2019 |
Zhu R, Poland B, Wada R, Liu Q, Musib L, Maslyar D, Cho E, Yu W, Ma H, Jin JY, Budha N. Exposure-Response-based Product-Profile-driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer. Cpt: Pharmacometrics & Systems Pharmacology. PMID 30762302 DOI: 10.1002/psp4.12394 |
0.18 |
|
2021 |
Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Cancer Chemotherapy and Pharmacology. PMID 34471960 DOI: 10.1007/s00280-021-04344-9 |
0.174 |
|
2017 |
Lu T, Fraczkiewicz G, Salphati L, Budha N, Dalziel G, Smelick GS, Morrissey KM, Davis JD, Jin JY, Ware JA. Combining "bottom-up" and "top-down" approaches to assess the impact of food and gastric pH on pictilisib (GDC-0941) pharmacokinetics. Cpt: Pharmacometrics & Systems Pharmacology. PMID 28748626 DOI: 10.1002/psp4.12228 |
0.168 |
|
2023 |
Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, Voskoboynik M, Rahman T, Budha N, Wu J, Marlow J, Yang S, Calvo E, Martin-Liberal J. A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. British Journal of Cancer. PMID 36797356 DOI: 10.1038/s41416-022-02128-3 |
0.134 |
|
2024 |
Galluppi GR, Ahamadi M, Bhattacharya S, Budha N, Gheyas F, Li CC, Chen Y, Dosne AG, Kristensen NR, Magee M, Samtani MN, Sinha V, Taskar K, Upreti VV, Yang J, et al. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical Pharmacology and Therapeutics. PMID 38519861 DOI: 10.1002/cpt.3245 |
0.12 |
|
2021 |
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R. Population repeated time-to-event analysis of exacerbations in asthma patients: a novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires. Cpt: Pharmacometrics & Systems Pharmacology. PMID 34346168 DOI: 10.1002/psp4.12690 |
0.114 |
|
Hide low-probability matches. |